Editorial Comment to Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan

被引：0
|
作者：
Kondo, Tsunenori [1 ]
机构：
[1] Tokyo Womens Med Univ, Adachi Med Ctr, Dept Urol, Tokyo, Japan
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2023年 / 30卷 / 09期
关键词：
D O I：
10.1111/iju.15256
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：777 / 778
页数：2
相关论文
共 50 条
  • [21] Efficacy of axitinib in renal cell carcinoma: Real-world experience at Gustave Roussy (IGR).
    Matias, Margarida
    Albiges, Laurence
    Lassau, Nathalle
    Benatsou, Baya
    Ablard, Charlotte
    Massarl, Francesco
    Escudler, Bernard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [22] Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis
    Sakae Konishi
    Shingo Hatakeyama
    Toshiaki Tanaka
    Yoshinori Ikehata
    Toshikazu Tanaka
    Naoki Fujita
    Yusuke Ishibashi
    Hayato Yamamoto
    Takahiro Yoneyama
    Yasuhiro Hashimoto
    Kazuaki Yoshikawa
    Toshiaki Kawaguchi
    Naoya Masumori
    Hiroshi Kitamura
    Chikara Ohyama
    Medical Oncology, 2019, 36
  • [23] Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan
    Hideaki Miyake
    Akira Miyazaki
    Ken-ichi Harada
    Masato Fujisawa
    Medical Oncology, 2014, 31
  • [24] Assessment of efficacy, safety and quality of life of 110 patients treated with sunitinib as first-line therapy for metastatic renal cell carcinoma: experience in real-world clinical practice in Japan
    Miyake, Hideaki
    Miyazaki, Akira
    Harada, Ken-ichi
    Fujisawa, Masato
    MEDICAL ONCOLOGY, 2014, 31 (06)
  • [25] Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis
    Konishi, Sakae
    Hatakeyama, Shingo
    Tanaka, Toshiaki
    Ikehata, Yoshinori
    Tanaka, Toshikazu
    Fujita, Naoki
    Ishibashi, Yusuke
    Yamamoto, Hayato
    Yoneyama, Takahiro
    Hashimoto, Yasuhiro
    Yoshikawa, Kazuaki
    Kawaguchi, Toshiaki
    Masumori, Naoya
    Kitamura, Hiroshi
    Ohyama, Chikara
    MEDICAL ONCOLOGY, 2019, 36 (01)
  • [26] HEALTH STATE UTILITIES IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE PEMBROLIZUMAB PLUS AXITINIB OR SUNITINIB
    Bensimon, A.
    Lai, Y.
    Xu, R.
    Bhattacharya, R.
    Shinde, R.
    VALUE IN HEALTH, 2022, 25 (07) : S554 - S554
  • [27] Avelumab/Axitinib versus Ipilimumab/Nivolumab: a Kent Oncology Centre Real-world Experience of First-line Combination Treatment for Metastatic Renal Cell Carcinoma
    Fenton, M.
    Bianchini, D.
    Brulinski, P.
    CLINICAL ONCOLOGY, 2023, 35 (02) : E237 - E237
  • [28] Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART)
    Kato, Taigo
    Nakano, Yuzo
    Hongo, Fumiya
    Katano, Hidenori
    Miyagawa, Tomoaki
    Ueda, Kosuke
    Azuma, Haruhito
    Nozawa, Masahiro
    Hinata, Nobuyuki
    Hori, Junichi
    Otoshi, Taiyo
    Shimizu, Nobuaki
    Aizawa, Mana
    Osada, Shingo
    Matsui, Akiko
    Oya, Mototsugu
    Eto, Masatoshi
    Tomita, Yoshihiko
    Shinohara, Nobuo
    Uemura, Hirotsugu
    INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (03) : 265 - 272
  • [29] The efficacy and safety of sorafenib in patients with renal insufficiency of advanced renal cell carcinoma: Real-world data of sorafenib in Japan
    Tatsugami, K.
    Oya, M.
    Kabu, K.
    Akaza, H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [30] Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma
    Du, Ella Xiaoyan
    Betts, Keith A.
    Wang, Travis
    Kitchen, Sophie A.
    He, Xuanhao
    Yin, Xin
    Guttenplan, Sarah B.
    Beauchamp, Karen
    Delgado, Andrew
    Rosenblatt, Lisa
    ONCOLOGY AND THERAPY, 2024, 12 (04) : 735 - 751
12345